Peripheral arterial disease (PAD) occurs when leg arteries become narrowed or blocked by plaque. These blockages can result in severe pain for patients, limited physical mobility, and life-threatening non-healing leg ulcers. According to the American Heart Association, this condition affects approximately 8 to 12 million Americans. With only about 25 percent of PAD patients undergoing treatment, it is a disease that is largely under-diagnosed and under-treated. If left untreated, PAD can lead to critical leg ischemia, a condition where not enough blood is being delivered to the leg to keep the tissue alive. Total loss of circulation to the legs and feet can cause gangrene and lead to amputation.
Hispanics adults hospitalized for treatment of symptoms of peripheral artery disease (PAD) were more likely to access this care by going to the emergency room (ER), and they experienced longer and more expensive hospitalizations than non-Hispanic white patients with PAD, according to preliminary research to be presented at the American Heart Association's Quality of Care and Outcomes (QCOR) Research Scientific Sessions 2021.
To track cardiovascular health, doctors measure blood pressure, cholesterol levels and blood sugar, among a number of other cardiovascular disease risk factors.
Peripheral artery disease (PAD) is a major cause of limb loss. It is estimated that PAD affects between 8.5 and 12 million Americans, with a prevalence that has increased by about 25 percent over the preceding decade.
People living with human immunodeficiency virus (HIV) have a higher risk of sudden cardiac death than people who do not have HIV, especially if the virus is not well-controlled or if they have other heart disease risk factors.
About one-fourth of people with diabetes develop painful foot ulcers, which are slow to heal due to low oxygen in the wound from impaired blood vessels and increased inflammation. These wounds can become chronic, leading to poor quality of life and potential amputation.
Poverty and Black race were associated with higher rates of lower leg amputation among people with peripheral artery disease who live in metropolitan areas, according to new research published today in a special issue of the Journal of the American Heart Association, an open access journal of the American Heart Association.
An internal transporter that enables us to use the copper we consume in foods like shellfish and nuts to enable a host of vital body functions also has the essential role of protecting the receptor that enables us to grow new blood vessels when ours become diseased, Medical College of Georgia scientists report.
Scientists at UC San Francisco have shown that gene-edited cellular therapeutics can be used to successfully treat cardiovascular and pulmonary diseases, potentially paving the way for developing less expensive cellular therapies to treat diseases for which there are currently few viable options.
Peripheral artery disease (PAD), or blockages in the arteries outside of the heart, affects more than 200 million people worldwide and 12.5 million people in the United States. Patients with this circulatory disorder may develop severe leg pain or unhealing wounds that require a minimally invasive revascularization procedure to open the blood vessels to improve blood flow.
Rivaroxaban, in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease (PAD) who underwent lower extremity revascularization, a procedure to open blocked arteries in the leg.
People with prediabetes were significantly more likely to suffer a heart attack, stroke or other major cardiovascular event when compared with those who had normal blood sugar levels, according to research being presented at the American College of Cardiology's 70th Annual Scientific Session.
The impact on lung cells of Heat not Burn products--a hybrid between traditional cigarettes and electronic vaping devices--may be no less harmful than that of conventional cigarettes, suggest the findings of a small comparative study, published online in the journal Thorax.
More blood thinners aren't automatically better, another study confirms. A new publication in JAMA Internal Medicine focuses on the minimal pros and the concerning cons of combining a daily aspirin with a drug from the newer class of anticoagulants that include apixaban, dabigatran, edoxaban and rivaroxaban.
Family history of early cardiac events in first degree relatives such as a parent or sibling is a major risk factor, especially for premature events. Currently, data on risks in close relatives of patients with a family history of premature heart attacks, chronic stable angina or peripheral vascular disease are sparse.
No pain means no gain when it comes to reaping exercise benefits for people with peripheral artery disease (PAD), reports a new Northwestern Medicine study.
In a new publication from Cardiovascular Innovations and Applications, Wenxiu Liu, Yutong Guo, Yue Liu, Jiaxing Sun and Xinhua Yin from The First Affiliated Hospital of Harbin Medical University, Heilongjiang, China consider calcium-sensing receptors of immune cells and diseases.
Percutaneous coronary intervention (PCI), commonly known as angioplasty with a stent, opens clogged arteries and saves lives. Despite its benefit in treating atherosclerosis that causes coronary artery disease, this common minimally-invasive procedure still poses severe complications for some patients.
Mid-term results of the first clinical trial designed specifically to evaluate the safety and effectiveness of two cell therapies that are showing early promise in treating angiitis-induced critical limb ischemia were released today in STEM CELLS Translational Medicine.
In the first human clinical trial, researchers at Massachusetts General Hospital and surgeons at Beth Israel Deaconess Medical Center have validated the practicality and accuracy of an oxygen-sensing liquid bandage that measures the concentration of oxygen in transplanted tissue
An interim analysis from the Swedish Drug-Elution Trial in Peripheral Arterial Disease (SWEDEPAD) has now been presented.